Theratechnologies Inc T.TH

Fool me 4 times shame on you... this is the 5th...

[SABBOBCAT]

I hear the optimism from some folks that this is merely a pivot on the learning path, but what I don't think is resonating with me until now is the repeated failures of this organization. They are becoming too many and too loud to ignore. 

1. Commercialization of Egrifta: This is an old old story some may or may not know
2. Re-commercialization of Egrifta: This is the more recent story we have seen slowly play out with lackluster results
3. Commercialization of Trogarzo: Never achieved a significant fraction of the projected market share, with delayed launch of IVPush/IM formula, and the abandonment of the european market. 
4. Phase 2/3 NASH: the "position of strength" appears to be balled up in the corner doing SFA. No material progression in years. 
5. TH1902: P1A delayed as they didnt want to admit to a lower dose so they scraped into 1B and realized that they now need to reconfigure again. so another 6-8 months of delays on top of the initial 6-8 months. 

Absent of a favorable partnership announcement in NASH or oncology, I don't see any near term upside that would prevent another OO. Yet management deemed a 6:30PM press release sufficient to communicate to investors how screwed they are with no planned call for further clarity? How disrespectful and out of touch are these folks? 

The only thing I can think of is their hand was forced somehow in communicating this. Was it the Cantor report that eluded to it that made them realize they inadvertently let it slip? or is there some other deal that is pending that requires the disclosure? Time will tell. 

SPCEO, I can only imagine the conversations you now have to have with your clients and I would not be surprised if this was the straw (or hay bale) that broke the camel's back, but if you do stay, I think you finally agree that something needs to be done about the culture and direction. 

Absense of big news or big change, I may need to finally say enough is enough and move on. It is going to be a tough puill to swallow as I broke every rule on this one and will take a long time to come back from this, but I cant ignore the greener pastures any longer.

[SPCEO1]

I will need to hear more before drawing any conclusions but I think we all knew any early stage cancer trial has meaningful risk associated with it. I noted that the risk increased when we did not hear any good results by mid-October. While we can certainly blame management for quite a few issues, in this case I am not sure we can. A result like this is hardly uncommon in the world of cancer

[LouisW]

Will you and your friends call them for further discussion to know the rationale behind the decision? I still believe in the TH1902. CMO said the adverse events mainly in of neuropathy and eye toxicity. Both eye cells and neuronal cells express relatively high SORT1, meaning TH1902 can find the cells which have SORT1 expression. We have two positive cases in prostate cancer and cancer experts

[Wino115]

We'll likely learn more, but the paradox is the trade-off you have to make with extremely ill patients who really can't deal with much in the way of side-effects. One of the issues is what we've discussed --the requirements to enter are you've exhausted ALL standard treatments. In other words, nothing is currently working on your cancer --you are succumbing and we can test to

[SABBOBCAT]

I appreciate the color wino. This is very helpful for less medically inclined folks such as myself. This is what I would have hoped management would cover in a call following a PR such as this to calm nerves and realign the story.  It is regrettable that hasn't happened and we are fortunate to have folks such as yourself on this board. 

[jeffm34]

The company needs to be stripped down immediately. They can not put one more dollar into cancer or NASH. They have 2 commercial products, that's it!  The 2 programs are available for licensing but TH can not commit any more resources to them if they hope to remain alive without massive dilution for shareholders. If they did indeed have a Chinese licensing deal on the table and never took

[qwerty22]

I am struggling to believe the safety signals haven't got bigger, unmanageable, that's what's causing the voluntary pause. There's probably still a fair number of patients to enroll. If this was still in the managable ballpark I think they might have stumbled on to see exactly where efficacy/safety landed in this still small trial. It feels as though something bigger must have

[jeffm34]

Stock price will be cut in half today. Not sure how some of you can say there was no upside on the cancer program built into the market cap before this news